BLOG

Immuneering to bolster cancer pipeline, expand services unit with $17M series A

Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}